| Literature DB >> 35516193 |
Sixing Pan1, Jianan Zhou1, Sujuan Zhou2, Zhangpeng Huang2,3, Jiang Meng4.
Abstract
Moutan Cortex (MC) and Moutan Cortex charcoal (MCC) are two kinds of Chinese medicinal materials widely used in traditional Chinese medicine (TCM) with opposite drug efficacy. And the contributions of the chemical component to the drug efficacy are still not clear. In our study, a support vector regression (SVR) model with particle swarm optimization (PSO) has been developed for simultaneously characterizing the pharmacokinetics (PK) and pharmacodynamics (PD) of MC/MCC. Then the contributions of the chemical component to the drug efficacy of MC/MCC are calculated by the weight analysis of SVR. The experimental results show that the effective substances found by the PSO-SVR model in MC and MCC are consistent with TCM theory. And the PSO-SVR model is a better model for PK-PD compared with the back-propagation neural network (BPNN). In conclusion, the PSO-SVR is a valuable tool that linked PK and PD profiles of MC/MCC with multiple components and identified the contributions of multiple therapeutic materials to the drug efficacy. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35516193 PMCID: PMC9055091 DOI: 10.1039/d0ra04111d
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1The PK–PD modeling using PSO-SVR algorithm.
Training set of PK–PD for Moutan Cortexa
| Time (h) | PK (content/μg mL−1) | PD (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gallic acid | 5-HMF | 3-H-2-M-4-P | Oxpaeoniflorin | 3,8-D-2-MC | Paeoniflorin | Benzoic acid | Methyl paraben | Quercetin | Paeonol | TXB2 | 6-Keto-PGFlα | |
| 0.08 | 78.06 | 22.89 | 3.18 | 0.96 | 65.06 | 84.19 | 17.98 | 0.69 | 89.32 | 2.97 | 1.12 | 0.05 |
| 0.25 | 88.72 | 33.84 | 3.67 | 1.21 | 80.75 | 114.71 | 24.20 | 1.61 | 120.70 | 3.35 | −0.07 | 0.63 |
| 0.5 | 102.00 | 36.25 | 4.11 | 1.23 | 107.34 | 184.15 | 35.60 | 1.92 | 248.61 | 4.42 | −0.38 | 0.60 |
| 0.75 | 133.14 | 51.90 | 2.52 | 1.27 | 120.85 | 75.15 | 39.79 | 3.13 | 256.99 | 6.02 | 0.41 | 0.89 |
| 1 | 113.30 | 64.61 | 2.15 | 1.46 | 78.55 | 53.40 | 54.21 | 1.43 | 270.83 | 2.20 | 0.89 | 1.26 |
| 2 | 96.66 | 119.27 | 1.44 | 1.55 | 37.11 | 53.62 | 51.24 | 0.50 | 301.84 | 4.14 | −0.10 | −0.53 |
| 3 | 73.65 | 103.69 | 1.08 | 1.50 | 36.57 | 35.84 | 65.02 | 0.67 | 412.90 | 4.77 | 0.63 | −0.02 |
| 4 | 63.71 | 76.60 | 1.36 | 1.73 | 22.61 | 52.76 | 127.25 | 0.56 | 451.64 | 3.00 | −0.02 | 1.06 |
| 6 | 46.25 | 58.06 | 0.75 | 1.02 | 23.00 | 52.06 | 69.82 | 0.60 | 219.12 | 2.11 | −0.82 | 1.19 |
| 8 | 45.90 | 22.82 | 0.97 | 1.04 | 17.96 | 44.03 | 71.83 | 0.30 | 287.27 | 1.33 | 0.94 | 0.92 |
| 10 | 42.48 | 15.21 | 0.90 | 0.96 | 11.36 | 36.26 | 61.01 | 0.27 | 351.53 | 1.05 | 0.99 | 0.34 |
| 12 | 31.11 | 9.97 | 0.72 | 0.90 | 5.61 | 22.03 | 31.37 | 0.17 | 206.96 | 0.94 | 0.55 | 2.04 |
TXB2, % = (Ctreated animals − Cmodel animal)/(Cmodel animal − Cblack animal) × 100%. 6-Keto-PGFlα, % = (Ctreated animals − Cmodel animal)/(Cmodel animal − Cblack animal) × 100%.
Training set of PK–PD for Moutan Cortex charcoala
| Time (h) | PK (content/μg mL−1) | PD (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gallic acid | 5-HMF | 3-H-2-M-4-P | Oxpaeoniflorin | 3,8-D-2-MC | Paeoniflorin | Benzoic acid | Methyl paraben | Quercetin | Paeonol | TXB2 | 6-Keto-PGFlα | |
| 0.08 | 109.76 | 145.36 | 7.45 | 0.00 | 19.63 | 86.97 | 7.81 | 0.55 | 39.96 | 2.78 | 0.85 | 0.50 |
| 0.25 | 114.10 | 211.68 | 12.45 | 0.00 | 19.13 | 101.35 | 4.60 | 1.57 | 49.51 | 3.40 | 1.47 | 0.47 |
| 0.5 | 161.24 | 309.53 | 22.32 | 0.00 | 49.98 | 179.54 | 9.33 | 2.63 | 83.47 | 3.60 | 1.88 | 1.05 |
| 0.75 | 247.45 | 358.91 | 9.16 | 0.00 | 55.01 | 62.49 | 10.86 | 2.85 | 102.44 | 5.11 | 1.12 | 0.43 |
| 1 | 223.14 | 422.25 | 6.69 | 0.00 | 21.02 | 48.45 | 11.33 | 2.59 | 130.29 | 3.23 | 1.44 | 0.82 |
| 2 | 133.16 | 455.35 | 2.46 | 0.00 | 19.40 | 53.92 | 18.96 | 0.72 | 150.92 | 3.19 | 1.69 | 1.80 |
| 3 | 88.43 | 269.97 | 2.01 | 0.00 | 16.33 | 63.23 | 19.22 | 0.64 | 207.95 | 1.86 | 2.46 | 0.83 |
| 4 | 44.24 | 185.84 | 1.60 | 0.00 | 7.12 | 63.70 | 19.85 | 0.89 | 100.01 | 2.50 | 2.42 | 0.48 |
| 6 | 40.66 | 144.41 | 1.30 | 0.00 | 6.82 | 58.14 | 24.68 | 0.73 | 123.57 | 3.68 | 1.52 | 1.66 |
| 8 | 36.64 | 30.68 | 0.89 | 0.00 | 7.03 | 60.58 | 22.36 | 0.33 | 141.34 | 3.60 | 2.93 | 1.02 |
| 10 | 28.99 | 18.82 | 0.54 | 0.00 | 6.64 | 47.74 | 14.47 | 0.30 | 94.21 | 2.49 | 1.91 | −0.60 |
| 12 | 27.63 | 6.83 | 0.45 | 0.00 | 4.79 | 15.01 | 9.45 | 0.19 | 62.31 | 2.40 | 0.87 | 4.08 |
TXB2, % = (Ctreated animals − Cmodel animal)/(Cmodel animal − Cblack animal) × 100%. 6-Keto-PGFlα, % = (Ctreated animals − Cmodel animal)/(Cmodel animal − Cblack animal) × 100%.
The optimal parameters for SVR calculated by PSOa
| Drug efficacy values | MC | MCC | ||
|---|---|---|---|---|
|
|
|
|
| |
| TXB2 | 92.721 | 42.244 | 61.188 | 9.858 |
| 6-Keto-PGFlα | 57.641 | 88.907 | 14.526 | 17.69 |
c is the penalty factors and σ is the radial basis function parameter.
Fig. 2(a) Output and APE of TXB2 for MC. (b) Output and APE of 6-keto-PGFlα for MC.
Fig. 3(a) Output and APE of TXB2 for MCC. (b) Output and APE of 6-keto-PGFlα for MCC.
The contributions of chemical concentration to drug efficacy for MC
| Components | TXB2 | 6-Keto-PGFlα |
|---|---|---|
| Gallic acid | −0.0828 | −0.5801 |
| 5-HMF |
|
|
| 3-Hydroxy-2-methyl-4-pyranone | −0.0382 | −0.4197 |
| Oxpaeoniflorin | −0.0316 | −0.1703 |
| 3,8-Dihydroxy-2-methylchromone | −0.1239 | −0.6188 |
| Paeoniflorin |
|
|
| Benzoic acid |
|
|
| Methyl paraben | −0.1357 | −0.3765 |
| Quercetin |
|
|
| Paeonol | −0.1784 | −0.4408 |
The contributions of chemical concentration to drug efficacy for MCC
| Components | TXB2 | 6-Keto-PGFlα |
|---|---|---|
| Gallic acid |
|
|
| 5-HMF |
|
|
| 3-Hydroxy-2-methyl-4-pyranone |
|
|
| Oxpaeoniflorin | 0 | 0 |
| 3,8-Dihydroxy-2-methylchromone |
|
|
| Paeoniflorin |
|
|
| Benzoic acid | −0.3633 | 0.2061 |
| Methyl paraben | −0.0313 | −0.0971 |
| Quercetin | −0.2949 | −0.2422 |
| Paeonol | −0.1301 | −0.0186 |
Results between proposed PSO-SVR and BPNN
| Drug efficacy values | MC | MCC | ||||||
|---|---|---|---|---|---|---|---|---|
| PSO-SVR | BPNN | PSO-SVR | BPNN | |||||
| RMSE | MAPE | RMSE | MAPE | RMSE | MAPE | RMSE | MAPE | |
| TXB2 | 0.031 | 5.31 | 0.069 | 7.82 | 0.029 | 4.65 | 0.57 | 7.74 |
| 6-Keto-PGFlα | 0.042 | 4.86 | 0.076 | 6.24 | 0.036 | 5.26 | 0.642 | 8.67 |